These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 6967055)

  • 1. Collaboration between specific anti-tumor immunity and chemotherapeutic agents.
    Yamamura Y; Proctor JW; Fischer BC; Harnaha JB; Mahvi TA
    Int J Cancer; 1980 Mar; 25(3):417-23. PubMed ID: 6967055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Host immune potentiation of drug responses to a murine mammary adenocarcinoma. II. Effect of melphalan therapy on the host immune system.
    Radov LA; Korn JH; Haskill JS
    Int J Cancer; 1976 Nov; 18(5):630-8. PubMed ID: 992900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunological responses to a murine mammary adenocarcinoma: cytolysis by armed monocyte and by antibody-dependent cellular cytotoxicity.
    Yamamura Y
    Oncology; 1980; 37(1):6-11. PubMed ID: 7350556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heterogeneity of murine mammary adenocarcinoma cell subpopulations. In vitro and in vivo resistance to macrophage cytotoxicity and its association with metastatic capacity.
    Yamamura Y; Fischer BC; Harnaha JB; Proctor JW
    Int J Cancer; 1984 Jan; 33(1):67-72. PubMed ID: 6693196
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The importance of antibody and macrophages in spontaneous and drug-induced regression of the T1699 mammary adenocarcinoma.
    Haskill JS; Key M; Radov LA; Parthenais E; Korn JH; Fett JW; Yamamura Y; DeLustro F; Vesley J; Gant G
    J Reticuloendothel Soc; 1979 Oct; 26(4):417-25. PubMed ID: 316009
    [No Abstract]   [Full Text] [Related]  

  • 6. Immunologic responses to a murine mammary adenocarcinoma. II. Monocyte effector activation by humoral factors.
    Yamamura Y
    Int J Cancer; 1977 May; 19(5):717-24. PubMed ID: 863548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunological responses to a murine mammary adenocarcinoma. Outgrowth of pulmonary occult metastases induced by immunosuppressive perturbations.
    Yamamura Y; Braunschweiger PG; Madyastha KR; Proctor JW
    Int J Cancer; 1984 Jan; 33(1):73-7. PubMed ID: 6693197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunologic responses to a murine mammary adenocarcinoma: in vitro production of specific killer cells is dependent on active T lymphocytes.
    Yamamura Y
    J Immunol; 1978 Jan; 120(1):286-92. PubMed ID: 75226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune response to inactivated syngeneic mammary adenocarcinoma cells. I. Role and regulation of antibody synthesis in DBA/2 mice.
    DeLustro F; Haskill JS
    J Natl Cancer Inst; 1980 Jan; 64(1):125-30. PubMed ID: 6928037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunologic factors influencing the intra-tumor localization of ADCC effector cells.
    Haskill S; Parthenais E
    J Immunol; 1978 Jun; 120(6):1813-7. PubMed ID: 659877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Host responses within solid tumors: non-thymus-derived specific cytotoxic cells within a murine mammary adenocarcinoma.
    Haskill JS; Yamamura Y; Radov L
    Int J Cancer; 1975 Nov; 16(5):798-809. PubMed ID: 1081078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ADCC effector cells in a murine adenocarcinoma. I. Evidence for blood-borne bone-marrow-derived monocytes.
    Haskill JS
    Int J Cancer; 1977 Sep; 20(3):432-40. PubMed ID: 903193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin 2 requirement for the in vitro generation of antitumor cytotoxicity by thymocytes from melphalan-cured MOPC-315 tumor bearers.
    Mokyr MB; Bartik MM; Ahn MC
    Cancer Res; 1989 Feb; 49(4):870-6. PubMed ID: 2783557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of resistance to MOPC-315 plasmacytoma after intralesional and intraperitoneal melphalan therapy of tumor-bearing BALB/c mice. II. Enhancement of in vitro cell-mediated cytotoxicity by combined chemotherapy-immunotherapy.
    Adler A; Keisari Y; Ofir R
    J Natl Cancer Inst; 1985 Feb; 74(2):429-36. PubMed ID: 3856051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IL-21 induces tumor rejection by specific CTL and IFN-gamma-dependent CXC chemokines in syngeneic mice.
    Di Carlo E; Comes A; Orengo AM; Rosso O; Meazza R; Musiani P; Colombo MP; Ferrini S
    J Immunol; 2004 Feb; 172(3):1540-7. PubMed ID: 14734732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunologic responses to a murine mammary adenocarcinoma. I. Passive transfer of immunity by sera from tumor-bearing mice.
    Yamamura Y; Virella G; Haskill JS
    Int J Cancer; 1977 May; 19(5):707-16. PubMed ID: 68018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Host immune potentiation of drug responses to a murine mammary adenocarcinoma.
    Radov LA; Haskill JS; Korn JH
    Int J Cancer; 1976 Jun; 17(6):773-9. PubMed ID: 947856
    [No Abstract]   [Full Text] [Related]  

  • 18. Lysis of antigenically unrelated tumor cells mediated by Lyt 2+ splenic T-cells from melphalan-cured MOPC-315 tumor bearers.
    Barker E; Wise JA; Dray S; Mokyr MB
    Cancer Res; 1989 Sep; 49(18):5007-15. PubMed ID: 2788494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of tumor-derived cytokines on the immune system of mice bearing a mammary adenocarcinoma. II. Down-regulation of macrophage-mediated cytotoxicity by tumor-derived granulocyte-macrophage colony-stimulating factor.
    Sotomayor EM; Fu YX; Lopez-Cepero M; Herbert L; Jimenez JJ; Albarracin C; Lopez DM
    J Immunol; 1991 Oct; 147(8):2816-23. PubMed ID: 1918995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunity to the T1699 murine mammary tumor. I. Thymic influence and long-term effect of irradiation on the humoral response.
    Parthenais E; Haskill S
    J Immunol; 1979 Sep; 123(3):1329-33. PubMed ID: 381522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.